WebThe CHAARTED trial was initially published in 2015 and an updated analysis was published in 2024 evaluating the survival benefit of docetaxel addition to ADT by volume status. 6 This trial was enriched for high volume disease (64.9% of total cohort) and 72.8% of patients presented with de novo disease. This updated analysis demonstrated that ... WebJan 11, 2024 · High-volume disease per CHAARTED criteria was defined as the presence of visceral metastasis or ≥4 bone lesions with ≥1 beyond the vertebral bodies and …
Long-term follow-up data from the CHAARTED trial THE
WebFor example, the CHAARTED trial defined high volume disease as the presence of visceral metastases and/or ≥4 bone lesions with ≥1 lesion beyond the vertebral bodies and pelvis. This study revealed the survival benefit of the upfront use of docetaxel only existed in mPC patients with high volume disease but not in those with low volume ... csネット 生協
Difference Between Volume and Capacity (with Comparison Chart) …
WebMetastatic disease burden was classified according to the CHAARTED volume definition 3, as well as the Yossepowitch 5 and LATITUDE 6 trial definitions: ... CHAARTED: 40.2% low-volume; 59.8% high-volume; CHAARTED: (with non-regional lymph nodes and bone metastasis in high-volume): 35.8% low-volume; 64.2% high-volume ... WebThe definition of high-volume disease used for this protocol was a combination of features from prior classifications. All the definitions included the presence of nonnodal, soft-tissue visceral ... WebJul 1, 2024 · Background: The CHAARTED and LATITUDE trials demonstrated a prolonged overall survival (OS) for metastatic hormone-naïve prostate cancer (mHNPC) patients … csネットワーク 熊本